PDF factsheet
      Z

antiplatelets drug in cardiovascular prevention for secondary prevention in patients with intermittent claudication, clinical trials results

aspirin versus placebo
CLIPS, 2007
oral aspirin 100 mg daily
versus
placebo
outpatients with stage I-II PAD documented by angiography or ultrasound, with ankle/brachial index <0.85 or toe index <0.6double blind
Follow-up duration: 20.7 months mean
Europe
Munich B, 1975
Aspirine 1500 mg / jour pendant 24 mois
versus
Placebo
NAdouble blind
Munich A, 1975
Aspirine: 1500 mg / jour
versus
Placebo
Données non disponiblesdouble blind
Schoop, 1983
groupe 1 : Aspirine 990 mg / j (pour mémoire : groupe 2 : Aspirine 990 mg / j + dipyridamole 225 mg/j)
versus
Placebo
AOMI stade non précisédouble blind
Follow-up duration: <5 y
Hess, 1985
groupe 1 : Aspirine 330 mg / j (pour mémoire : groupe 2 : Aspirine 330 mg / j + dipyridamole 75 mg / j)
versus
Placebo
AOMI stade non précisésingle blind
aspirin + dipyridamol versus placebo
Hess (2), 1985
Aspirine Dipyridamole 330 mg / j 225 mg / j
versus
Placebo
patients with occlusive arterial disease in the lower extremitiesdouble blind
Schoop (2), 1983
Aspirine Dipyridamole 990 mg / j 225 mg /j
versus
Placebo
AOMI stade non précisédouble blind
VA study, 1986
Aspirine + Dipyridamole 975 mg / j 225 mg /j
versus
Placebo
non-insulin-dependent diabetic men with either a recent amputation for gangrene or active gangrenedouble blind
Follow-up duration: 46 months
clopidogrel versus aspirin
CAPRIE, 1996
clopidogrel 75 mg once daily
versus
aspirin 325 mg once daily
patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial diseaseDouble blind
Follow-up duration: mean 1.91 years
16 countries
CAPRIE (PAD subgroup), 1996
Clopidogrel 75 mg
versus
Aspirine 325 mg
patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial diseasedouble blind
Follow-up duration: 1.91 y
cloricromene versus placebo
CRAMPS, 2000
Cloricromène : 100 mg, 2 fois / jour / voie orale + aspirine : 160 mg / jour pendant 6 mois .
versus
placebo + aspirine: 160 mg/ jour pendant 6 mois.
Stade de la maladie : II, pendant 3.1 années d'ancienneté en moyenne dans les 2 groupes double blind
Follow-up duration: 6 months
ketanserine versus placebo
Thulesius, 1987
Ketanserin 60 mg / j pdt 2 semaines 120 mg / j ensuite
versus
Placebo
patients with intermittent claudication (stade II)double blind
Follow-up duration: 6 months
Walden, 1991
Ketanserin 60 mg / j pdt 1 mois 120 mg / j ensuite
versus
Placebo
patients with intermittent claudication (stade II)double blind
Follow-up duration: 15 months
PACK, 1996
Ketanserin 40 mg / j pdt 1 mois 80 mg / j ensuite
versus
Placebo
patients over 40 years old who had had documented intermittent claudication for at least two months and in whom the ratio of systolic blood pressure in the ankle to that in the arm was less than or equal to 0.85 in both arteries of at least one footdouble blind
Follow-up duration: 1 y
picotamide versus placebo
Coto, 1989
Picotamide 900 mg / j
versus
Placebo
patients with peripheral occlusive arterial disease of the lower limbs at functional stage II of the Fontaine classificationdouble blind
Follow-up duration: 6 months
ADEP, 1993
Picotamide 600 mg / j
versus
Placebo
patients with peripheral obstructive arterial disease (stade II+)double blind
Follow-up duration: 18 months
Neirotti, 1994
Picotamide 900 mg / j
versus
Placebo
patients with peripheral arterial disease (PAD) at functional stage 2 of the Fontaine classification and with intermittent claudication for at least six months double blind
Follow-up duration: 18 months
suloctidil versus placebo
Adriaensen, 1976
Suloctidil 200 mg / j
versus
Placebo
patients suffering from intermittent claudication ( stade II)double blind
Follow-up duration: 2 months
Verhaeghe, 1981
Suloctidil 200 mg / j
versus
Placebo
patients with intermittent claudication (stade II)double blind
Follow-up duration: 6 months
Jones, 1982
Suloctidil 300 mg / j
versus
Placebo
patients suffering from intermittent claudication (stade II)double blind
Follow-up duration: 6 months
Holm, 1984
Suloctidil 300 mg / j
versus
Placebo
AOMI stade IIdouble blind
Follow-up duration: 2.75 y
ticagrelor versus clopidogrel
EUCLID, 2016
NCT01732822
ticagrelor (90 mg twice daily)
versus
clopidogrel (75 mg once daily)
patients with symptomatic peripheral artery disease
Follow-up duration: 30 months (median)
ticlopidine versus placebo
Ellis, 1986
Ticlopidine 500 mg/j
versus
Placebo
AOMI stade IIdouble blind
Follow-up duration: 6 months
Hurlow, 1980
Ticlopidine : 100 -500 mg / jour pendant 2 mois.
versus
Placebo
Données non disponiblesdouble blind
Krause, 1980
Ticlopidine : 500 mg pendant 4 mois
versus
Placebo
Données non disponiblesdouble blind
Katsumara, 1982
Ticlopidine 500 mg/j
versus
Placebo
patients with ischemic ulcers due to chronic arterial occlusiondouble blind
Follow-up duration: 6 semaines
Aukland, 1982
Ticlopidine 500 mg/j
versus
Placebo
men with atherosclerotic intermittent claudication and haemorheological abnormalitiesdouble blind
Follow-up duration: 1 y
Stiegler, 1984
Ticlopidine 500 mg/j
versus
Placebo
AOMI stade IIdouble blind
Cloarec, 1986
Ticlopidine 500 mg/j
versus
Placebo
AOMI stade non précisédouble blind
Follow-up duration: 1 y
Arcan, 1988
Ticlopidine 500 mg/j
versus
Placebo
patients with chronic intermittent claudication due to obstructive peripheral vascular disease (stade II)double blind
Follow-up duration: 6 months
Balsano, 1989
Ticlopidine 500 mg/j
versus
Placebo
patients with intermittent claudication (stade II)double blind
Follow-up duration: 21 months
STIMS, 1990
Ticlopidine 500 mg/j
versus
Placebo
patients with intermittent claudication (stade II)double blind
Follow-up duration: 5.6 y
EMATAP, 1993
Ticlopidine 500 mg/j
versus
Placebo
AOMI stade non précisédouble blind
vorapaxar versus placebo (on top aspirin)
TRA-2P TIMI 50, 2012
NCT00526474
vorapaxar (SCH 530348) 2.5-mg daily
versus
placebo (added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel)
patients with a known history of atherosclerosis (MI, ischemic stroke, or peripheral vascular disease)double-blind
Follow-up duration: 2.5 y (median)

  Options


in first

in second

  Filter